

EQA round: GP2/23 - Detection of Monoclonal Components

Deadline: 22.9.2023

Setup: Slovakia; minimal size of the groups n = 5

RoM = robust average

SD = standard deviation

CV = coefficient of variation

N_{tot} = total number of the resultsN_{out} = number of the results removed before calculation

AV = assigned value

CVP = consensus of all participants

U_{AV} = expanded uncertainty of the assigned value (k = 2)D_{max} = acceptable difference

LL = lower limit

UL = upper limit

N_{eva} = number of the results assessedN_{suc} = number of successful resultsS_{rel} = relative success

Test Sample Group	[unit]	RoM	SD	CV [%]	N _{tot}	N _{out}	Comparability					N _{eva}	N _{suc}	S _{rel} [%]	
							AV	U _{AV}	D _{max}	LL	UL				
(247) Gammopathies (quantity 1) (plasma)	[g/L]				16							16	14	88	
Sample A												16	14	88	
All results		13,5	2,7	20	16	0	CVP	12,8	0,76	33%	8,57	17,1	16		
(279) Total protein (plasma)	[g/L]				15							15	15	100	
Sample A												15	15	100	
All results		48,6	1,2	2,5	15	0	CVP	48,9	0,27	8%	44,9	52,9	15		
(314) FLC kappa (plasma)	[mg/L]				13							13	13	100	
Sample A												13	13	100	
All results		2760	420	15	13	0	CVP	2710	140	50%	1350	4070	13		
(315) FLC lambda (plasma)	[mg/L]				13							13	13	100	
Sample A												13	13	100	
All results		2,63	0,4	15	13	0	CVP	2,86	0,16	±3	0	5,86	13		
(545) Gammopathies (quantity 1) (urine)	[g/L]				6							6	6	100	
Sample B												6	6	100	
All results		0,089	0,017	19	6	0	CVP	0,093	0,026	66%	0,031	0,155	6		
(546) Gammopathies (quantity 2) (urine)	[g/L]				3							3	3	100	
Sample B												3	3	100	
Other					3	0						3			
							3x								
(550) Total protein (urine)	[g/L]				14							8	8	100	
Sample B												8	8	100	
Other					14	0						8			
							1x 0, 3x 1, 1x 12, 3x 58, 2x 60, 2x 75, 1x 179, 1x 998								